Home | Donate | Contact Us | Physicians | 1.888.STJOES1
About St. Joseph's

St. Joseph’s Ronald Caputo, MD, FACC, Pens Article on Robotics in the Cath Lab


SYRACUSE - St. Joseph’s Hospital Health Center’s Ronald P. Caputo, MD, FACC, FSCAI, interventional cardiologist and medical director for the interventional cardiology service line, recently authored an article about the CorPath System for Cardiovascular News. The CorPath System is the first and only FDA 510(k) cleared robotic-assisted technology to aid interventional cardiologists in placing stents and balloons in patients with coronary artery disease (CAD). Developed by Corindus Vascular Robotics, CorPath is designed to enhance coronary angioplasty procedures with added precision and accuracy. St. Joseph’s is the first hospital offering robotic-assisted angioplasties outside metro New York City.

St. Joseph’s has been using the CorPath system for a few years now, having participated in the CorPath® PRECISE trial. Interventional Cardiologists Ronald P. Caputo, MD, FACC, FSCAI, Michael Fischi, MD, FACC, FSCAI, and Alan Simons, MD, FACC, FSCAI were investigators in the sponsored clinical trial, which evaluated the safety and effectiveness of the CorPath 200 System in delivering and manipulating coronary guidewires and stents in percutaneous coronary interventions (PCI) procedures.  St. Joseph’s was one of only eight hospitals in the world evaluating this new technology.

“The significantly improved control, visualization and measurement a physician can experience through the CorPath System are a testament to how the solution will set the future standard in angioplasty procedures,” said Dr. Caputo. “The millimeter by millimeter precision enabled through the technology allows greater accuracy in the measurement of blockages and placement of stents and leads to improvements in the quality of the care we deliver to patients – which is most critical to the overall mission of healthcare.”

CAD, characterized by plaque buildup that restricts blood flow in the arteries, is a widespread and life-threatening disease. It is the most common form of heart disease and the leading cause of death in America. Traditionally, percutaneous coronary intervention (PCI), commonly known as an ‘angioplasty,’ is the most common treatment for CAD. In this procedure, a balloon is used to physically open an artery blockage and help improve blood flow. During an angioplasty, interventional cardiologists often use stents, a wire metal mesh tube, to prop open the artery and keep it open following the procedure. While angioplasty procedures remain one of the most frequently performed procedures in the United States with nearly one million cases annually, the procedure has remained largely unchanged for decades.

“At St. Joseph’s, we are always working to provide the best available care available through the most advanced technologies, and the CorPath System reinforces our dedication to better clinical outcomes for our patients and safety for our physicians,” said John Cannizzaro, cardiovascular service line administrator for St. Joseph’s. “We are proud to be the first facility in New York, outside of New York City, to have taken a step towards the future of vascular procedures through the integration of the CorPath System.”

The CorPath System allows interventional cardiologists to perform the procedure remotely, away from the patient bed side. Seated in a radiation-protected cock-pit, the physician uses a joystick to robotically advance catheters, angioplasty balloons and stents to clear the blockage and restore blood flow. Additionally, the technology provides interventional cardiologists with the ability to accurately measure blockages and precisely position stents, which may lead to fewer stent implants.

St. Joseph’s Hospital Health Center is a non-profit, 431-bed hospital and health care system in Syracuse, New York, providing services to patients in 16 counties in Central New York State. Through prevention programs and the latest diagnostic treatment procedures, St. Joseph's works with patients to achieve optimum long-term health. A 14-time winner of the National Research Corporation Consumer Choice award, St. Joseph’s is affiliated with Franciscan Companies and sponsored by the Sisters of St. Francis. 

#          #          #

CUTLINE: Ronald P. Caputo, MD, FACC, FSCAI, interventional cardiologist and medical director for the interventional cardiology service line, pictured here, recently authored an article about the CorPath System for Cardiovascular News. The CorPath System is the first and only FDA 510(k) cleared robotic-assisted technology to aid interventional cardiologists in placing stents and balloons in patients with coronary artery disease (CAD). Developed by Corindus Vascular Robotics, CorPath is designed to enhance coronary angioplasty procedures with added precision and accuracy. St. Joseph’s is the first hospital offering robotic-assisted angioplasties outside metro New York City.